Pharmaust - Media & News, page-54

We have been hitting some great milestones, with the Healey Platform announcement being significant, and good comms from management. Yet the share price languishes. I must admit I haven't seen any valued added by the firm involved in the cap raise. Pre the cap raise there was some capping going on IMO around 23/24 , and IMO,we can still see the share price being held down. I think the SPP will be oversubscribed and allocations cut back. The share price pre raise was 24 cents (MC 93.4m), now it is circa $100m (with $10m in the bank) - overall reduction in EV at current price of 22 cents (reduction in value). The price has struggled to get up from the cap raise price, with constant selling into 22.5, in light of good announcements. I would have thought that the Healey announcement was good enough to get the price back to 25 cents (minimum) and work up from there, but here we are. It is frustrating to watch but it is a buy opportunity while this continues.